Trade Chugai Pharmaceutical Co., Ltd. - 4519 CFD
Add to favourite- Summary
- Historical Data
| Spread | 29.8 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.011244% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.010978% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | JPY | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | Japan | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5005.8 |
| Open | 5097.6 |
| 1-Year Change | 43.99% |
| Day's Range | 5044.8 - 5107.7 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 2, 2024 | 5091.2 | -21.6 | -0.42% | 5112.8 | 5112.8 | 5034.3 |
| May 1, 2024 | 5005.8 | -20.1 | -0.40% | 5025.9 | 5092.0 | 5002.3 |
| Apr 30, 2024 | 5021.8 | -11.2 | -0.22% | 5033.0 | 5063.8 | 4954.1 |
| Apr 26, 2024 | 4841.4 | 5.0 | 0.10% | 4836.4 | 4893.8 | 4712.2 |
| Apr 25, 2024 | 4864.8 | -10.5 | -0.22% | 4875.3 | 5032.8 | 4822.7 |
| Apr 24, 2024 | 5128.5 | -87.8 | -1.68% | 5216.3 | 5358.0 | 5101.5 |
| Apr 23, 2024 | 5163.4 | 43.7 | 0.85% | 5119.7 | 5196.4 | 5102.8 |
| Apr 22, 2024 | 5136.5 | 186.0 | 3.76% | 4950.5 | 5144.5 | 4938.1 |
| Apr 19, 2024 | 4904.7 | -154.9 | -3.06% | 5059.6 | 5059.6 | 4881.5 |
| Apr 18, 2024 | 5078.6 | 67.8 | 1.35% | 5010.8 | 5078.6 | 4981.9 |
| Apr 17, 2024 | 5066.6 | -6.0 | -0.12% | 5072.6 | 5090.6 | 5016.7 |
| Apr 16, 2024 | 5106.5 | 117.7 | 2.36% | 4988.8 | 5122.5 | 4983.4 |
| Apr 15, 2024 | 5079.6 | -8.9 | -0.17% | 5088.5 | 5119.5 | 5041.7 |
| Apr 12, 2024 | 5227.2 | 16.9 | 0.32% | 5210.3 | 5241.2 | 5147.4 |
| Apr 11, 2024 | 5225.2 | 81.8 | 1.59% | 5143.4 | 5236.2 | 5113.5 |
| Apr 10, 2024 | 5208.3 | -114.6 | -2.15% | 5322.9 | 5363.9 | 5177.3 |
| Apr 9, 2024 | 5377.8 | -20.0 | -0.37% | 5397.8 | 5406.8 | 5327.9 |
| Apr 8, 2024 | 5372.8 | -47.9 | -0.88% | 5420.7 | 5455.6 | 5342.9 |
| Apr 5, 2024 | 5425.7 | -80.8 | -1.47% | 5506.5 | 5535.4 | 5412.7 |
| Apr 4, 2024 | 5548.3 | -47.9 | -0.86% | 5596.2 | 5650.1 | 5537.4 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Chugai Pharmaceutical Co., Ltd. Company profile
About Chugai Pharmaceutical Co Ltd
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chugai Pharmaceutical Co Ltd revenues increased 27% to Y999.76B. Net income increased 41% to Y303B. Revenues reflect Net Sales increase of 27% to Y802.84B, Royalties and other operating revenues increase of 28% to Y196.92B. Dividend per share increased from Y55.00 to Y76.00. Basic Earnings per Share excluding Extraordinary Items increased from Y130.66 to Y184.29.
Equity composition
FY'03, the Co. changed FY end from March to December. FY'94-'02 WAS & FY'04 Q1 &Q3 WAs & O/S were estimated. 3/05 & 9/05, WAS, O/S, DPS were estimated. FY'06 Q3 & '07 Q1, Q3 WAS& DWAS were estimated, and its WAS was used as O/S. FY'08 1Q WAS & DWAS were estimated and WAS was used as o/s. FY'08 Q3 WAS estimated and used as o/s.
| Industry: | Pharmaceuticals (NEC) |
日本橋三井タワー15f
日本橋室町2-1-1
CHUO-KU
TOKYO-TO 103-8324
JP
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com